埃格林医药 is a fast-growing biopharmaceutical company focused on innovative drug R&D, notably developing the COVID-19 injectable EG-009 series. The company reports it obtained three U.S. FDA clinical approvals in just over a year. On March 15 it completed a ¥100 million Series A financing led by Shenzhen Tiantu Investment, with Shenzhen Share Investment and other investment institutions participating. Proceeds will fund continued new-drug R&D, including the EG-009A phase II clinical trial and other clinical-stage and preclinical projects. Management plans to accelerate development of the EG-009 series, advance multiple internally developed projects into the clinic, and strengthen collaborations with domestic and international innovative drug companies. Company leadership emphasized the financing provides important funding security to optimize and expand the R&D pipeline.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2021